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ABSTRACT 
Objectives:  Proton pump inhibitors (PPIs) are among the most prescribed medications worldwide, however, 
there is growing concern regarding potential negative effects on bone health. The aim was to examine the effect of 
dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women. 
Methods:  Data were included from 4432 participants (born 1921-26) in the 2002 survey of the Australian 
Longitudinal Study on Women‘s Health. Medication data were from the national pharmaceutical administrative 
database (2003-2012, inclusive). Fractures were sourced from linked hospital datasets available for four major States 
of Australia. Competing risk regression models used PPI exposure as a time-dependent covariate and either time to 
first osteoporosis medication prescription or fracture as the outcome, with death as a competing risk. 
Results:   Of the 2328 PPI users and 2104 PPI non-users, 827 (36%) and 550 (26%) became users of 
osteoporosis medication, respectively. PPI use was associated with an increased risk of subsequent use of 
osteoporosis medication (adjusted sub-hazard ratio [SHR]=1.28; 95% confidence interval [CI]=1.13-1.44) and 
subsequent fracture (SHR=1.29, CI=1.08-1.55). Analysis with PPI categorized according to defined daily dose 
(DDD), showed some evidence for a dose-response effect (osteoporosis medication: <400 DDD: SHR=1.23, 
CI=1.06-1.42 and ≥400 DDD: SHR=1.39, CI=1.17-1.65, compared with non-users; SHRs were in the same range 
for fractures). Esomeprazole was the most common PPI prescribed (22.9%). Analysis by type of PPI use showed an 
increased subsequent risk for: (1) use of osteoporosis medication for rabeprazole (SHR=1.51, CI=1.08-2.10) and 
esomeprazole (SHR=1.48, CI=1.17-1.88); and (2) fractures for rabeprazole (SHR=2.06, CI=1.37-3.10). Users of 
multiple types of PPI also had increased risks for use of osteoporosis medication and fractures. 
Conclusion:  An appropriate benefit/risk assessment should be made when prescribing PPIs, especially for 
esomeprazole and rabeprazole, as osteoporosis and fracture risks were increased in this cohort of elderly females 
subsequent to PPI prescription. 
  
Highlights 
 Proton pump inhibitor (PPI) use in elderly (>77 years) women was associated with increased risk of 
decreased bone health. 
 Increased risk of subsequent osteoporosis medication was associated with the most commonly prescribed 
PPI, esomeprazole, and with rabeprazole and use of multiple different PPIs. 
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 Rabeprazole, and use of multiple different PPIs, was also associated with adverse bone consequences. 
 There may be a dose-response relationship between PPI use and osteoporosis medication or fractures. 
 Risks of harms need careful assessment before prescribing PPIs to elderly women to ensure benefits 
outweigh potential adverse effects on bone. 
 
Keywords 
Proton pump inhibitors; omeprazole; esomeprazole; fractures; osteoporosis medication. 
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1. Introduction 
Acid-related upper gastrointestinal disorders are common in the developed world [1]. Consequently, proton pump 
inhibitors (PPIs) to treat these disorders are among the most widely prescribed medications worldwide [1, 2]. PPIs 
are indicated for several acid-related upper gastrointestinal disorders, including gastro-oesophageal disease (GERD), 
dyspepsia, peptic ulcer disease and as prophylaxis for non-steroidal anti-inflammatory drugs-associated upper 
gastrointestinal complications [3]. Due to their effectiveness and perceived short-and long-term safety, PPIs account 
for 95% of acid suppressing medication prescriptions [1]. In Australia, PPI prescribing tripled from 45 in 2001 to 
130 defined daily dose (DDD)/1000 concession beneficiaries/day in 2005 [4]. With 6.9 million prescriptions in 
2014,  PPIs are the third most prescribed drug group by volume and the fourth highest cost prescribed drug group in 
Australia [5]. The total number of dispensed prescriptions for PPIs increased by 28% from approximately 74 million 
prescriptions in 2002 to 95 million prescriptions in 2009 [6].  
More recently, a growing concern is the safety of PPIs; several adverse effects of long term PPI use have been 
reported, including decreased bone quality [3, 7]. Warnings about PPIs and potentially increased fracture risk have 
been issued in Australia and in the US [8, 9]. In 2011, a meta-analysis by Kwok et al. [7] (observing 4 prospective 
cohort studies and 8 retrospective studies, of which 6 case-control studies) confirmed an increased risk of fracture 
following PPI use, presumably due to the development of osteoporosis. In 2014, a prospective cohort study by 
Moberg et al. [10] found that postmenopausal women using PPI‘s were having a more than double increased 
fracture risk (odds ratio=2.53, confidence intervals (CI)=1.28–4.99). If a causal relationship exists between PPIs and 
fractures, the predisposing factors for fractures are expected to be affected. However, studies examining associations 
between PPI use and bone mineral density (BMD) found none or little evidence for an association between PPI use 
and the development of osteoporosis [11-15]. In contrast, a study by Maggio et al. [16] found that PPI use was 
significantly associated with decreased trabecular BMD, possibly an early marker of osteoporosis. One study found 
that PPI-users were more likely to subsequently be prescribed osteoporosis medication than non-users and that 
increased duration of therapy was associated with higher risks of osteoporosis medication prescription [1]. Three 
studies examining the effect of PPI use on calcium uptake used the dual isotope test (golden standard for intestinal 
calcium absorption) and these showed no evidence for decreased calcium absorption among PPI users [17-19]. 
Overall, it remains unclear whether PPIs indeed have a significant effect on bone metabolism [7].  
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Previous studies typically compared all PPI users with non-users, while the effect may depend on dose or type of 
PPI. Investigation of dose and type of PPI use not only gives more insight into the reported adverse effects on bone 
health, but also may have important implications for prescribing. The study objective was to examine the effect of 
dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women 
from 2003 to 2011. It was hypothesized that PPI use negatively influences bone health resulting in both increased 
osteoporosis medication prescription and fracture incidence. 
 
2. Methods 
2.1 Study sample 
Data were from the Australian Longitudinal Study on Women‘s Health (ALSWH), a prospective study of 
demographic, social, physical, psychological, and behavioural variables and their effect on women‘s health, well-
being and health service use [20].  In 1996, participants were selected from the database of the Health Insurance 
Commission that ran the national health insurance scheme (Medicare). All Australian citizens and permanent 
residents, regardless of age or income, were included in the Medicare database. The ALSWH includes three birth-
cohorts of women, i.e. younger women born in 1973-1978, mid-age women born in 1946-1951, and older women 
born in 1921-26. The ALSWH study methods have been approved by the Human Research Ethics Committees of 
the Universities of Newcastle and Queensland and all participants signed informed consent. More detailed 
information about the ALSWH can be found at www.alswh.org.au. 
For the current study, data were used from the older women (born 1921-1926). Prescriptions for PPI and 
osteoporosis medication were publically subsidized and neither group of medications is available for purchase over-
the-counter. In 1996, 12432 older women completed the initial survey (response rate 37-40%) [20]. Since then, five 
follow-up surveys have been completed at 3-year intervals. As linked pharmaceutical data were available from 2002 
onward, the 2002 survey (ages 76-81 years, n=8646) was used as baseline. Data were excluded from women who: 
(1) completed a short version of the survey; (2) did not consent to data linkage; (3) died before 2003; (4) received 
PPI and/or osteoporosis medication in 2002; and (5) had missing values for confounders , resulting in data available 
from 4432 participants (Figure 1).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
Medication data were from the Pharmaceutical Benefits Scheme (PBS) administrative database [21], which records 
for all Australian residents every prescription medicine dispensed with government subsidy. In PBS, each 
dispensing claim is coded with an item number, which is specific for the drug strength, dose form and quantity. Item 
numbers map to the World Health Organisation (WHO) Anatomical Therapeutic Chemical (ATC) classification 
system. Data about fractures were from admitted patient hospital datasets linked to ALSWH participants.  Hospital 
linked data were only available for 4 of the 8 states and territories: New South Wales, Queensland, South Australia 
and Australian Capital Territory (62% of the study sample). 
 
2.2 PPI exposure 
PPI-users were defined as having  ≥1 prescription recorded for omeprazole, pantoprazole, lansoprazole, rabeprazole 
or esomeprazole between January 2003 and December 2011 (inclusive). Indications and restrictions for PPI subsidy 
have been published [22]. PPIs were not available over the counter in Australia during this time. Participants who 
started osteoporosis medication before (n=361) or at the same time (n=14) as PPI were classified as PPI non-users. 
In addition, PPI use was categorized according to the type of PPI used. Participants who used more than one type of 
PPI during follow-up were categorized as ‗‗multiple type‘‘ users. The total volume of PPIs used in the study period 
was converted to a cumulative DDD  per participant (DDD per dispensing x total number of dispensings per 
participant), according to the WHO ATC/DDD index 2013 [23]. Three categories were created: non-user, <400 
DDD, ≥400 DDD. 
 
2.3 Subsequent use of osteoporosis medication 
Users of osteoporosis medication  were defined as having  ≥1 prescriptions recorded for alendronate, zoledronic 
acid, risedronate, disodium etidronate, strontium ranelate, denosumab, teriparatide, raloxifene, ergocalciferol, 
calcitriol, colecalciferol or calcium supplements specific for osteoporosis between January 2003 and December 2011 
(inclusive). Indications for subsidy have been published previously [24]. Ergocalciferol, calcitriol, colecalciferol and 
calcium supplements were dispensed with government subsidy only after diagnosis with osteoporosis after minimal 
trauma fracture. 
 
2.4 Subsequent fractures  
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Admission data and International Classification of Diseases-10 (ICD-10) codes for any fractures recorded between 
January 2003 and June 2011 (inclusive) in the hospital administrative records were used as data sources to identify 
participants with fractures.  
 
2.5 Other variables 
The variables obtained by self-report in the 2002 ALSWH survey and included in the analysis and were alcohol 
consumption, smoking, level of education, age, physical functioning, physical activity, area of residence, body mass 
index (BMI), number of general practitioner consultations, and chronic conditions. BMI (kg/m
2
) was calculated 
using self-reported height and weight. Alcohol status was categorized as ‗‗low-risk drinker‘‘, ‗‗non-drinker‘‘, 
‗‗rarely drinks‘‘, ‗‗risky drinker‘‘, ‗‗high-risk drinker‘‘ [25]. Smoking status (1999 survey) was defined as non-
smoker or smoker based on the question ‗‗How often do you currently smoke cigarettes or any tobacco products?‘‘  
Level of education (1996 survey) was assessed as the highest qualification completed, ranging from ―no formal 
qualification‖ to ―university degree or higher‖. Physical functioning was based on the physical functioning subscale 
(0-100) of the SF-36, which measures health-related quality of life [26]. Self-rated health was assessed with the 
question ―In general, would you say your health is: excellent, very good, good, fair or poor?‖ Physical activity was 
measured with the Active Australia Survey questions about time spent walking, and in moderate and vigorous 
leisure time activities.  Physical activity was calculated as the weekly total minutes spent walking and in moderate 
and vigorous activity multiplied by their metabolic equivalent value (MET): [(walking x 3.0 METs) + (moderate-
intensity activity x 4.0 METs) + (vigorous-intensity activity x 7.5 METs)], and categorized as: none (<40); low (40-
<600); moderate (600-<1200); or high (1200+) MET.min/week [27]. Area of residence was categorized as urban, 
rural, and remote. Number of chronic conditions was assessed by summing the self-report of  hypertension, arthritis, 
heart attack, angina pectoris, other heart disorder, diabetes, asthma, bronchitis, stroke, cancer (except skin cancer), 
depression, and dementia (range 0-12). 
To control for potential modifying or confounding effects of other medications based on the literature [28-30], 
further data were obtained from the linked PBS database.  The medications considered were thyroid hormones, 
hormone replacement therapy (HRT), thiazide diuretics, selective serotonin receptor inhibitors (SSRI), aromatose 
inhibitors and antiepileptic drugs and glucocorticoids (high dose tablets [>20mg per tablet] and high dose inhalants 
[minimum strength of 400mcg per activation as high dose cot]). Participants were defined as users of each of these 
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medications if they had >3 prescriptions dispensed.  For glucocorticoids, only long-term, high-dose use was 
considered, in line with indications for government subsidy for bisphosphonate treatment of corticosteroid-induced 
osteoporosis. 
 
2.6 Statistical analysis 
Sample characteristics were compared between PPI-users and non-users with the t-test (age, BMI), the Mann-
Whitney U test (chronic conditions, physical functioning) and the chi-squared test (all categorical variables). A p-
value of <0.05 was considered statistically significant. All analyses were conducted with STATA version 11.2 
(StataCorp LP. College Station, TX). 
 
The association between PPI use and subsequent use of osteoporosis medication and fractures were examined using 
competing risk regression models, and reported as sub-hazard ratios (SHRs) with 95% CI. The SHR is the ratio of 
hazards associated with the cumulative incidence function in the presence and absence of the exposure variable. PPI 
was set up as a time-dependent covariate to prevent both immortal selection bias (which occurs when follow-up 
starts with first PPI exposure; i.e. time when use of osteoporosis medication, fractures or death cannot occur is 
omitted for PPI-users) and immortal misclassification bias (which occurs when participants who become PPI-users 
after the start of study are classified as PPI-users during the whole follow-up) [31, 32]. At the start of follow-up 
(January 1, 2003), all participants were PPI non-users. For each participant, the survival time in days was calculated 
from start to either first use of osteoporosis medication, first fracture, death or end of the follow-up (December 31, 
2011 for use of osteoporosis medication and June 30, 2011 for fractures), whichever occurred first. For participants 
who had a PPI dispensing before the first osteoporosis medication dispensing, fracture, death or end of follow-up, 
two records were created. Thus, PPI-users were included in the analyses twice: first as a non-user with time to 
censoring (i.e. the time of the first PPI dispensing), then as a PPI-user with time from first dispensing to the time of 
first osteoporosis medication dispensing, fracture, death or the end of follow-up. This approach allowed maximum 
use of the available data and standardized the start of follow-up for all participants, independent of PPI status.  
Robust standard errors were used to account for counting PPI-users twice.  
The analyses were conducted without adjustment and after adjustment for age and area of residence, plus any of the 
survey and other medication variables that were statistically significantly associated with PPI use and/or use of 
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osteoporosis medication or fractures. Potential interaction with any of the other medications was tested by adding 
interaction terms (PPI use x medication).  Subsequently, the model was stratified for medication use if a statistically 
significant interaction was identified. 
To determine a potential effect of dosage and duration of treatment on subsequent use of osteoporosis medication or 
fractures, analyses were repeated for PPI categorized according to DDD. In this model, DDD was the time-
dependent variable with ≥400 DDD users put in the model first as a non-user, then as a <400 DDD user from the day 
of first PPI claim and subsequently as a ≥400 DDD user from the day of first claim adding up to >400 DDD. To 
examine the effect of type of PPI, the model fitting was repeated for each type of PPI separately compared with PPI 
non-users.  
 
3. Results 
During an average follow-up of 6.6 years for use of osteoporosis medication, 2328 of the 4432 participants started 
PPI therapy. During an average follow-up of 7.6 years for fractures, 1396 of the 2734 participants with available 
linked hospital data started PPI therapy (Figure 1). PPI-users were more likely than PPI non-users to score lower on 
self-reported health; have a higher BMI and more chronic conditions; have lower physical functioning; and use other 
medications (i.e. glucocorticoids, SSRI and antiepileptics) (Table 1).  
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Figure 1 Flowchart of women excluded and included in the current study (2 column fitting image) 
Abbreviations: ALSWH, Australian Longitudinal Study on Women’s Health; PPI, proton pump inhibitor; OM, 
osteoporosis medication. 
Descriptive caption: In 1996, 12432 older women completed the baseline survey of the ALSWH. Since then, five 
follow-up surveys have been completed at 3-year intervals. As pharmaceutical data were available from 2002 
onward, the 2002 survey (ages 76-81 years, n=8646) was used as baseline.  
 
Table 1. Descriptive characteristics of ALSWH women (oldest cohort) in 2002 
  
 
PPI-users  
(N=2328),  
n (%) 
PPI non-users 
(N=2104), 
n (%) 
 
p value 
Women (born 1921-26) who returned 
ALSWH survey 3 (2002) 
N=8646 
Women who did not withdraw from data 
linkage 
N=8100 
Women who were alive and had no 
records of prior PPI use at Jan 1, 2003 
N=4432 
PPI non-users 
(2003-2010) 
N=2104 
 
550 (26.1%)  
OM users 
Exclusion of women who died prior to Jan 
1, 2003 (n=94) 
 
Exclusion of women who used PPIs 
and/or OM in 2002 (n=2655) 
 
Exclusion of women with incomplete data 
on confounders (n=919) 
 
Exclusion of women who withdrew 
consent for data linkage (n=546) 
PPI users 
(2003-2010) 
N=2328 
 
827 (35.5%)  
OM users 
PPI non-users 
(2003-2010) 
1338 
 
229 (17.6%) 
fractures 
PPI users 
(2003-2010) 
N=1396 
 
350 (24.6%) 
fractures 
 
Exclusion of women living in states for 
which no hospital data were available 
(n=1698) 
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Age Mean (SD) 78.2 (1.4) 78.3 (1.5) 0.33 
Area of residence   Urban 1001 (43.0) 877 (41.7) 0.57 
 Rural 1283 (55.1) 1181 (56.1)  
 Remote 44 (1.9) 46 (2.2)  
Marital status   Married/De facto 1072 (46.2) 922 (43.9) 0.30 
Living situation  Community-dwelling 2289 (99.2) 2065 (99.1) 0.24 
Level of education  No formal qualifications 623 (28.0) 569 (28.2) 0.26 
 School/high school 1232 (55.4) 1074 (53.1)  
 Trade/certificate/diploma  270 (12.1) 282 (14.0)  
 University degree or higher 100 (4.5) 96 (4.8)  
Self-reported health  Excellent 97 (4.2) 175 (8.4) <0.001 
 Very good 648 (27.9) 766 (36.6)  
 Good  1010 (43.5) 808 (38.6)  
 Fair  512 (22.1) 307 (14.7)  
 Poor 53 (2.3) 39 (1.9)  
Body mass index 
 
Mean (SD) 25.6 (4.6) 25.2 (4.6) 0.008 
Chronic conditions 
a
 Median [IQR] 2 [1-2] 1 [0-2] <0.001 
Need help daily tasks Yes Yes 231 (10.1) 182 (8.8) 0.13 
Nr GP consultations >12 279 (12.1) 172 (8.3) <0.001 
Smoking status   Smoker 100 (4.7) 88 (4.6) 0.86 
Alcohol status   Risky drinker 76 (3.6) 71 (3.7) 0.76 
Physical activity  Inactive 786 (35.8) 669 (33.6) 0.51 
 Low 626 (28.5) 577 (29.0)  
 Moderate 346 (15.8) 325 (16.4)  
 High 438 (20.0) 418 (21.0)  
Physical functioning Median [IQR] 65 [40-81] 75 [50-85] <0.001 
Thyroid hormones  >3 dispensings 334 (14.3) 261 (12.4) 0.06 
Glucocorticoids
 b
  >3 dispensings 203 (8.7) 75 (3.6) <0.001 
HRT >3 dispensings 29 (1.3) 18 (0.9) 0.21 
Thiazide diuretics >3 dispensings 601 (25.8) 501 (23.8) 0.12 
SSRI >3 dispensings 459 (19.7) 267 (12.7) <0.001 
Aromatase inhibitors  >3 dispensings 44 (1.9) 36 (1.7) 0.66 
Antiepileptics  >3 dispensings 122 (5.2) 79 (3.8) 0.02 
SD standard deviation; IQR interquartile range; GP general practitioner; HRT hormone replacement therapy; SSRI 
Selective Serotonin Receptor Inhibitors 
Numbers and proportions per category are presented except where indicated otherwise. Numbers may not add up to 
total N because of missing data. 
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a
 Chronic conditions include hypertension, arthritis, heart attack, angina pectoris, other heart disorder, diabetes, 
asthma, bronchitis, stroke, cancer (except skin cancer), depression, dementia (range 0-12) 
b
 Only high dose and inhalants were included. 
 
Of the PPI-users, 827 (35.5%) subsequently started using osteoporosis medication and 470 (20.2%) died, whereas of 
the non-users, 550 (26.1%) started using osteoporosis medication and 485 (23.1%) died. PPI use was associated with 
an increased risk of subsequent use of osteoporosis medication (SHR=1.32, CI=1.17-1.49). This association 
remained statistically significant after adjustment for area of residence, age, BMI, number of chronic conditions, 
physical functioning and use of thyroid hormones, high dose glucocorticoids, aromatase inhibitors and SSRI (Table 
2). The cumulative incidence function comparing use of osteoporosis medication between PPI-users and non-users is 
shown in Figure 2. No statistically significant interactions were found for PPI use with any other medications; 
stratification for other medication use was therefore not required.  
Hospital linked data were available for 62% of this cohort of ALSWH participants (2734/4432). These data showed 
a significant higher risk of fracture after PPI use (SHR=1.34, CI=1.12-1.60) (Table 3). This association remained 
statistically significant after adjustment. 
Analysis with PPI categorized according to total dosage (DDD) showed some evidence for a dose-response effect 
(Tables 2 and 3). Esomeprazole and pantoprazole were the most frequently dispensed PPIs (22.9% and 19.4% of 
the PPI users, respectively). Analysis by type of PPI use showed that rabeprazole (SHR=1.51, CI=1.08-2.10), 
esomeprazole (SHR=1.48, CI=1.17-1.88) and multiple type (SHR=1.57, CI=1.32-1.87) users had an increased 
subsequent use of osteoporosis medication (Table 2). Rabeprazole  (SHR=2.06, CI=1.37-3.10) and multiple type 
(SHR=1.59 CI=1.24-2.05) users also had increased subsequent fractures (Table 3).   
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Figure 2 Cumulative incidence of osteoporosis medication use in PPI users and non-users (Single-column fitting 
image) 
Abbreviations: PPI, proton pump inhibitor. 
Descriptive caption: Cumulative incidence function of osteoporosis medication use for PPI non-users and PPI users 
during study follow-up (2003-2012). 
 
Table 2. Association between PPI use and subsequent use of osteoporosis medication 
  
N (%) 
OM-user 
N (%) 
Deceased 
N (%) 
Unadjusted 
SHR  (95% CI) 
p- value Adjusted 
a
  
SHR (95% CI) 
p-value 
non-user 2104 (47.5) 550 (26.1)  485 (23.1) 1 [reference]  1 [reference]  
PPI-user 2328 (52.5) 827 (35.5) 470 (20.2) 1.32 (1.17-1.49) <0.001 1.28 (1.13-1.44) <0.001 
  
non-user 2101 (47.4) 550 (26.2) 482 (22.9) 1 [reference]  1 [reference]  
<400 DDD 1083 (24.5) 347 (32.0) 276 (25.5) 1.27 (1.10-1.47) 0.001 1.23 (1.06-1.42) 0.006 
≥400 DDD 1245 (28.1) 480 (38.6) 194 (15.6) 1.42 (1.20-1.68) <0.001 1.39 (1.17-1.65) <0.001 
        
non-user 2101 (47.4) 550 (26.2) 482 (22.9) 1 [reference]  1 [reference]  
omeprazole 376 (8.5) 123 (32.7) 113 (30.1) 1.06 (0.81-1.37) 0.68 1.00 (0.77-1.31) 0.98 
pantoprazole 452 (10.2) 147 (32.5) 83 (18.4) 1.04 (0.79-1.39) 0.79 1.01 (0.76-1.35) 0.93 
0
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lansoprazole 30 (0.7) 8 (26.7) 9 (30.0) 1.04 (0.38-2.85) 0.94 1.01 (0.36-2.80) 0.99 
rabeprazole 219 (4.9) 73 (33.3) 41 (18.7) 1.56 (1.13-2.16) 0.007 1.51 (1.08-2.10) 0.02 
esomeprazole 532 (12.0) 193 (36.3) 98 (18.4) 1.48 (1.17-1.87) 0.001 1.48 (1.17-1.88) 0.001 
multiple types 722 (16.3) 283 (39.2) 129 (17.9) 1.71 (1.45-2.02) <0.001 1.57 (1.32-1.87) <0.001 
SHR sub-hazard ratio; CI confidence interval; PPI proton-pump inhibitor; OM osteoporosis medication 
a 
Adjusted for area of residence, age, body mass index,  number of chronic conditions, physical functioning, and use 
of each of the following medicines: thyroid hormones, high dose glucocorticoids, aromatase inhibitors, selective 
serotonin receptor inhibitors. 
 
Table 3. Association between PPI use and subsequent fracture 
  
N (%) 
Fracture 
N (%) 
Deceased 
N (%) 
Unadjusted 
SHR  (95% CI) 
p- value Adjusted 
a
  
SHR (95% CI) 
p-value 
non-user 1338 (48.9) 235 (17.6) 259 (19.4) 1 [reference]  1 [reference]  
PPI-user 1396 (51.1) 344 (24.6) 241 (17.3) 1.34 (1.12-1.60) 0.002 1.29 (1.08-1.55) 0.006 
  
non-user 1338 (48.9) 235 (17.6) 259 (19.4) 1 [reference]  1 [reference]  
<400 DDD 669 (24.5) 159 (23.8) 144 (21.5) 1.28 (1.04-1.59) 0.02 1.25 (1.01-1.55) 0.04 
≥400 DDD 727 (26.6) 185 (25.5) 97 (13.3) 1.42 (1.12-1.81) 0.004 1.36 (1.06-1.75) 0.02 
        
non-user 1337 (48.9) 235 (17.6) 259 (19.4) 1 [reference]  1 [reference]  
omeprazole 216 (7.9) 53 (24.5) 56 (25.9) 1.23 (0.85-1.79) 0.27 1.14 (0.78-1.67) 0.50 
pantoprazole 289 (10.6) 69 (23.9) 48 (16.6) 1.06 (0.72-1.56) 0.78 1.03 (0.69-1.53) 0.89 
lansoprazole 17 (0.6) 4 (23.5) 4 (23.5) 1.19 (0.30-4.66) 0.80 1.31 (0.33-5.23) 0.71 
rabeprazole 159 (5.8) 39 (24.5) 18 (11.3) 2.13 (1.42-3.18) <0.001 2.06 (1.37-3.10) <0.001 
esomeprazole 275 (10.1) 55 (20.0) 53 (19.3) 1.23 (0.85-1.79) 0.28 1.20 (0.83-1.74) 0.33 
multiple types 441 (16.1) 124 (28.1) 62 (14.1) 1.66 (1.30-2.11) <0.001 1.59 (1.24-2.05) <0.001 
SHR sub-hazard ratio; CI confidence interval; PPI proton-pump inhibitor 
a 
Adjusted for area of residence, age, body mass index,  number of chronic conditions, physical functioning, and use 
of each of the following medicines: thyroid hormones, high dose glucocorticoids, aromatase inhibitors, selective 
serotonin receptor inhibitors. 
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4. Discussion 
The results from this prospective cohort study support the hypothesis that PPI use is associated with an increased 
risk of subsequent use of osteoporosis medication and fractures in older women. These associations were strongest 
in the users of esomeprazole and rabeprazole. There was some evidence for a dose-response association.  
Osteoporosis medications are subsidized on PBS for women with a BMD T-score of <-3 or a minimal trauma 
fracture, which means that this outcome includes women with a low BMD, women with a fracture and women with 
both low BMD and a fracture. The PBS administrative database does not distinguish between these diagnoses. In our 
subsample with hospital data, 32.5% had both osteoporosis medication and a fracture, which suggests that use of 
osteoporosis medication in this population mainly reflects the low BMD diagnosis. The results for both outcomes 
pointed in the same direction, which strengthens the evidence for a negative association between PPI use and bone 
health. Most other studies examined associations between PPI use and only one of these or other indicators of bone 
health (e.g. BMD). Our findings are consistent with the only other study [1] that used osteoporosis medication as an 
indicator of bone health. The results of studies with other outcomes are inconsistent. A meta-analysis  by Kwok et 
al. [7] confirmed an increased fracture risk after the use of PPIs . In contrast, only one [13] of five prospective 
studies [11-15] found a significant negative association between PPI use and BMD at the hip, but not at other sites. 
Additionally a negative association was found for PPI use and trabecular BMD, but not for cortical BMD by Maggio 
et al. [16]. Except for the prospective cross-sectional study by Targownik et al. [11], the studies investigating PPI 
use and BMD were prospective cohort studies (Canadian Multicentre Osteoporosis Study (CaMos) [12], Women‘s 
Health Initiative (WHI) Observational Study and Clinical Trials [13], Osteoporotic Fractures in Men Study (MrOS) 
and Study of Osteoporotic Fractures (SOF) [14], and  Study of Women‘s Health Across the Nation (SWAN) [15]).  
Several explanations are possible for the discrepancy in findings with fractures and BMD in previously published 
studies. First, in a study by Wainwright et al. [33] half of the older women with fractures did not have a BMD in the 
osteoporotic range. Therefore measuring BMD may not be an accurate reflection of fracture risk. Furthermore, a 
recent randomized controlled trial by Itoh et al. [34] showed that bisphosphonate (an osteoporosis medicine) in 
combination with PPI use is more effective regarding physical fitness and BMD than solely bisphosphonate use. 
These results could reflect a more protective value of osteoporosis medication regarding fracture risk in PPI users 
due to improved physical fitness rather than a ‗healthy‘ BMD. Second, it could be that the mechanism explaining the 
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relationship between PPI use and fracture risk is not by decreasing BMD, but by other aspects of bone micro-
architecture which are not measured with DEXA scans [35]. Third, it may be that PPI use affects the fall risk and 
subsequently the fracture risk, without having a direct effect on bone quality [36]. Fourth, the inconsistent findings 
may be explained by differences between studies in study design and sample characteristics. Variations in inclusion 
and exclusion criteria between studies may have influenced the prevalence of both PPI and the outcome. Typically, 
studies have excluded participants with a fracture or osteoporosis medication before initiation of PPIs, rather than 
included them as PPI non-users, which may have led to immortal time bias [32]. Immortal time bias appears in 
pharmacoepidemiological cohort studies when the study design requires the treated group to survive until the 
treatment begins and results in overestimation of the effect sizes [31]. Fifth, variation in the types of PPI studied 
may also explain differences between studies, as we found that some but not all PPIs were associated with increased 
OAM use and fracture risk. More prospective studies examining the associations between types of PPIs and a 
combination of bone health measures are needed to understand mechanisms behind the relationship between PPI use 
and fractures. Including PPI use as a time-varying covariate is essential to avoid immortal time bias. 
The current findings provide some evidence of a dose-response relationship between PPI use and subsequent 
adverse bone health indicators. Although there was a trend of increased effect with increased total dose, this was not 
statistically significant (i.e. the confidence intervals overlapped).  Our measure of cumulative dose included both 
dose and duration component. In a meta-analysis by Kwok et al.[7], increased duration of PPI use was associated 
with higher risk ratios for fractures. Two more recent studies showed evidence for an increased fracture risk after 
long-term PPI use in older adults [10, 37]. In contrast, a study by Soriano et al. [38] showed a higher hip fracture 
risk after short-term PPI use, but not after long-term PPI use. It could be that in this study, PPI users who experience 
adverse effects on the short term switched to a different type of PPI or an H2 blocking agent resulting in a null effect 
on the long-term. This is supported by our finding that risks for fracture and use of osteoporosis medication were 
particularly high among those who used multiple types of PPIs. Given these inconclusive findings, future research 
should differentiate between dose and duration to better understand their potential influences on bone health.  
When the analyses in the present study were repeated for each type of PPI separately, increased use of osteoporosis 
medication and risk of fractures were found for users of rabeprazole. Additionally an increased risk for subsequent 
use of osteoporosis medication was found for users of esomeprazole. Multiple PPI users also showed increased use 
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of osteoporosis medication and subsequent fracture risk. So far, no other studies have analyzed specific effects of 
PPI type on bone health. The higher risk of osteoporosis medication and fractures after rabeprazole than other PPIs, 
could be supported by  the results of a study by Ishizaki et al. [28], in which the biotransformation of rabeprazole in 
the liver differed from other PPIs. Esomeprazole is a single enantiomer of omeprazole and logic would dictate that 
esomeprazole should be given at half the dose of omeprazole for equivalent efficacy. However, this is not the case in 
clinical practice and in fact esomeprazole is often given at twice the dose (presumably four times as potent) as 
omeprazole, and it could be that the association of osteoporosis medication and fractures with esomeprazole is just 
because of the higher dose of active PPI being given. Furthermore, findings from a study by Kirchheiner et al. [39] 
showed higher clinical potency for rabeprazole and esomeprazole, which is consistent with the current findings of 
increased subsequent prescription of osteoporosis medication after rabeprazole and esomeprazole use. Additionally, 
a prospective study by Bahtiri et al. [40] found that only esomeprazole use out of 4 studied PPI types, was 
significantly associated with a decreased BMD. Esomeprazole was a new drug at the time of the study, first 
receiving PBS subsidy in 2002. Hence a smaller proportion of esomeprazole (as sole PPI) users had data available 
for investigation of subsequent fracture (52%); they would have been more likely to be classified as multiple users, 
swopping from other PPIs. The lack of association between esomeprazole and risk of fracture is possibly an artefact 
of timing and requires further investigation in a larger cohort of users of this medication alone. If confirmed in other 
studies, this difference in risk between types of PPIs could have important clinical implications for prescribing 
practice. This is particularly relevant as esomeprazole has become the most widely prescribed PPI in Australia since 
first subsidy in 2002 and was prescribed to 12% of the total cohort of elderly women in this study (and over a fifth 
of the PPI users) [5].     
The strengths of this current study include the large sample size (n=4432), the prospective cohort design, adjustment 
for main confounders and an advanced analytical model. We have unique linked datasets, including many factors in 
addition to the medication dispensed, for each woman. The model took into account competing risks (death) and 
avoided immortal time bias (i.e. selection and/or misclassification bias) [31], by analysing PPI use as a time-
dependent covariate.   
Several limitations should be taken into account when interpreting the current results. Although many confounders 
were included, residual confounding may exist. Other studies have suggested some potential confounding variables 
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that were not measured in the current study, including vitamin B12 deficiency, community acquired pneumonia, 
clostridium difficile, Helicobacter pylori [3, 41] and celiac disease [42]. The large population based case-control 
study by Lam et al. [41] on PPI use and vitamin B12 deficiency, showed a significant association between previous 
and current PPI use and the existence of a vitamin B12 deficiency. In addition a recent review by Bailey et al. [43] 
found that vitamin B12 deficiency is associated with an increased fracture risk, whereas no significant effect of a 
vitamin B12 deficiency on BMD was found. Vitamin B12 deficiency could be a mediator rather than a confounder 
in the current study. Vitamin B12 deficiency caused by PPI use, could perhaps be considered as a potential 
mechanism leading to an increased fracture risk in PPI users, but further data would be required to explore this 
hypothesis. Higher dose corticosteroid use only was considered, not lower dose which might possibly be a residual 
confounder [35]. To measure co-morbidity, insufficient information was available to use validated indices such as 
those developed by Charlson or Elixhauser and we were limited to using number of chronic conditions reported 
from a selected list. The accuracy of self-report of chronic conditions varies across conditions, but is generally 
accepted for use in epidemiological studies where clinical examination of each of the conditions is not feasible [44, 
45].  The proportion of participants with 12+ GP consultations was greater in PPI users than non-users (Table 1). 
The higher rate of health services use among PPI users may suggest that these women were more likely to be 
diagnosed with or treated for osteoporosis based on exposure to physicians alone. However, the number of GP 
consultations did not differ between participants with and without use of osteoporosis medication and additional 
adjustment for GP consultations did not alter the results for use of osteoporosis medication (SHR=1.28, CI=1.13-
1.45, p<0.001 for PPI users compared with non-users). No information was available about compliance with PPI 
use; therefore, the study is based on dispensed PPIs rather than actual intake. It is known that osteoporosis is an 
underdiagnosed as well as undertreated condition [46]. Although treatment with osteoporosis medication may not be 
a good measure of osteoporosis given the compliance issues, it is likely that when first diagnosed with osteoporosis 
most patients will be dispensed an osteoporosis medication at least once. As our outcome was based on time to the 
first prescription, it is likely that we included the majority patients who had an osteoporosis diagnosis. Furthermore, 
a previous study in this sample showed substantial agreement between self-reported medication use and osteoporosis 
treatment [24]. The fractures outcome was based on hospital admission data, which means that only those fractures 
were included that led to hospital admission. No information is available of fractures that did not require 
hospitalization. However, as these community-dwelling women were quite elderly, it is likely that the majority of 
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fractures would have resulted in hospital admission. Finally, comparing sample characteristics between participants 
who were included with those who were excluded in the data analyses, suggested that included participants were 
more educated, healthier and had better lifestyles and levels of functioning. Hence, the current sample represents a 
group of relatively healthy older women (77-82 at the start of follow-up) and the study results may not be 
generalizable to other age groups and to men.  
In March 2013, the American College of Gastroenterology published new guidelines for the treatment of GERD, 
which reflect the ongoing doubts and concerns about potential adverse effects of PPI treatment. In these guidelines, 
the potential adverse effects of PPI use on bone are mentioned, but without implications for the prescription of PPIs 
[47]. However, the current results add to the evidence that PPI use is associated with decreased bone quality. The 
impact of PPI use expressed in terms of population attributable risk (= [proportion of cohort that are PPI users* 
[relative risk-1]]/[1+[proportion of cohort that are PPI users*[relative risk-1]]) is above 12, suggesting that both use 
of  osteoporosis medication and fractures in the population could be reduced by more than 12% if none of this 
cohort had used PPIs. 
Given the widespread use of PPIs and the high morbidity and mortality associated with osteoporotic fractures, an 
increased risk of fractures and osteoporosis attributable to PPI use could lead to a notable effect in the population 
health and health-related costs. Moreover a recent study by Huang et al. [48] showed that there was no effect of 
osteoporosis treatment with calcitriol  in people using esomoprazole. These findings highlight the need for a more 
careful approach to PPI prescription, as treating resulting osteoporosis may not be easy. As PPI treatment is often 
continued without verification or repeated confirmation of indication and/or lowest dose prescription, treatment on 
demand and step-down therapy should be considered more often [3, 49].  
 
5. Conclusion 
PPI use was associated with significantly increased subsequent use of osteoporosis medication and fractures. These 
associations existed for use of rabeprazole and esomeprazole.  This is important as esomeprazole was the most 
commonly prescribed PPI (22.9% of PPI users). The current results support the hypothesis that PPI use negatively 
affects bone health. These findings foreshadow the need for a more cautious approach than the current widespread 
prescribing of PPIs. Different PPIs may have differing effects on changing bone quality. 
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